The novel small molecule TFF3 inhibitor, AMPC, could potentially be utilized as a single agent or in combination with 5-FU to improve current clinical treatment in TFF3 positive CMS4 CRC. This evidence concerns the gene TFF3 and colorectal carcinoma.